Emily Lewis, MS, CCRP, is a leader in Digital Medicine at UCP Pharma with a passion for improving healthcare and using advanced technologies such as generative artificial intelligence. She is driven to maximize the good and deliver on the promise that AI holds for making the world a better place.
My name is Emily Lewis, Artificial Intelligence and Innovation Lead within Digital Care Transformation at UCB Pharma. I am based in Denver, Colorado.
What led you to go into your research field?
I have a strong desire to improve patient care, outcomes, and the overall healthcare system in the United States. At the same time, I have a keen interest in advanced technologies and their applications and believe in their potential to revolutionize healthcare. My experience pioneering Decentralized Clinical Trials (DCTs) led me to an interest in wearable technology and novel biomarkers of disease. Involvement in such projects, developing algorithms for wearables or software as a medical device, then got me very interested in traditional machine learning, and eventually generative artificial intelligence (GenAI). I’m particularly interested in using AI to enhance diagnostic accuracy and reduce clinician error and burnout. My belief is that AI will be very important in tailoring treatments to individual patients based on their unique characteristics as well as improving access to care.
What type of research are you currently doing?
I’ve been in clinical research since 2007, so roughly 17 years. Currently, I am involved in researching how generative AI, particularly large language models, can be used to transform care delivery models and improve physician referrals and patient communication, engagement, and understanding. Researching generative AI in care delivery settings is important in efforts to speed earlier detection and better management of disease. It also holds the promise of improved treatment efficacy with more tailored therapeutic approaches.
How does it do that?
GenAI can analyze vast amounts of data to uncover patterns and insights that can inform clinical decision making and further research. It opens up new areas of research, particularly in better understanding more complex medical conditions which were previously difficult to study. The hope is that, ultimately, GenAI can provide more equitable access to care with tailored interventions at a more economic cost, thereby improving patient outcomes and public health.
What is a typical day for you like?
I spend my time writing study proposals and protocols, presenting to steering committees, reading peer-reviewed publications (like Karger’s), and writing company position papers on our strategic plans for the use of AI both near term and long term. These strategic plans are subsequently reviewed by the executive leadership as well as our board. Also, I am involved in several consortia, academic and industry partnerships, and alliances, which allows UCB to collaborate with, contribute to, and learn from the external ecosystem. We bring in external innovation, contribute to policy discussions and best practices, and provide thought leadership in conversations about emerging technology.
Emily, 5th from left, at the Pharmaceutical Management Science Association (PMSA) Conference in Denver, Colorado
What motivates you the most about your current work?
I am motivated by the ability to contribute to improving healthcare efficiency, reducing healthcare disparities, and enhancing public health at scale. AI is a tool that could be used for both good and evil in this world, so I am doing my best to ensure we maximize those good use cases and deliver on the promise that AI holds for generally making the world a better place.
What is your vision for the future of your scientific/medical specialty?
Working within particularly complex conditions in neurology, I am particularly interested in how AI will assist clinicians in their ability to provide more effective treatments to patients with fewer side effects. In my perspective, AI-driven drug discovery can identify new therapeutic targets and accelerate the development of novel treatments for some of the most difficult neurological disorders. I also believe that AI will assist in uncovering disease mechanisms and provide a more robust understanding of what causes neurological conditions.
What advice would you give to a researcher or healthcare professional starting out?
I would say to gain hands-on experience with internships, multi-disciplinary projects, and collaborations which focus on understanding, solving, or building solutions for real clinical problems with AI. The importance of implementation science also cannot be overstated. Always remember to consider the patient’s perspective and aim to improve their overall experience with the healthcare system.
What motivated you to apply to become a Karger Ambassador?
I first become aware of Karger when they came out with their Digital Biomarkers journal. I became a Karger Ambassador a little over a year ago. And I enjoy being involved in thought leadership around AI as well as digital care transformation. Karger offers a great platform to learn, connect, and share with others of various backgrounds and experiences. I haven’t published many articles and always thought that publishing was for those with PhDs or MDs. Since then, I have come to realize that this is a fallacy, and the research I’m involved in absolutely deserves an outlet. I wanted to learn the inner workings of how to get published, what time commitment it requires, and how one might go about drafting manuscripts.
What is your vision for your future?
I see myself becoming a Chief Innovation Officer or Chief AI Officer, contributing to publications which advance the field in AI both on paper and in clinical practice, addressing unmet patient needs.
How do you switch off from a busy day at work?
I’m in a lot of activities with my daughter. She’s in parent-tot classes in music, soccer, swimming, gymnastics, and snowboarding, believe it or not. I keep her busy and challenge her the best I can. And I love listening to the NEJM AI podcast as well as the People of AI podcast from Google and I enjoyed reading “The AI Revolution in Medicine: GPT-4 and Beyond,” by Peter Lee, Carey Goldberg, and Isaac Kohane. In my time away from my daughter, I enjoy snowboarding myself and have season passes to many of the great resorts in Colorado.
Emily attending Google I/O in San Francisco with Google Women Techmakers
Emily Lewis is a trailblazing innovator and leader in the realm of digital health and AI. With nearly two decades of experience, she has made significant contributions to the development and adoption of cutting-edge digital health solutions. Her passion for using technology to improve patient outcomes and advance healthcare has earned her recognition as one of Fierce Healthcare’s Rising Stars in HealthTech.
Emily gained valuable experience working in various clinical research settings, including in academia, contract research organizations (CROs), pharmaceutical companies, and start-ups. These experiences allowed her to develop a deep understanding of the healthcare landscape and the potential for digital health solutions to revolutionize patient care. Within her current role, Emily serves as UCB Biopharma’s resident subject matter expert in AI. In continuously following industry trends and engaging in internal and external initiatives, she translates and evaluates their impact on the company, clients, and products. Cultivating relationships with key decision makers and industry leaders, Emily is an active participant and advocate in many initiatives that strive to increase the adoption of health IT, interoperability, access to health data, and patient engagement. In collaboration with other thought leaders, Emily has been instrumental in identifying ways to increase the adoption of digital tools which can improve patient care and reduce healthcare waste and decrease expenditure.
As a thought leader, Emily has 13,000 followers on LinkedIn and thrives on being a part of the most cutting-edge conversations shaping the future of healthcare. She desires to break down silos and create a social movement to initiate meaningful, sustainable, systemic change for collective impact. Emily enjoys listening and learning from others in the field and believes that, together, we can achieve a future where the healthcare system works for everyone. Supporting many strategic initiatives in change management and digital transformation, Emily has demonstrated a commitment to harnessing the power of IT to positively transform health and healthcare. Her leadership and impact on the industry, advocacy for inclusive policies, and commitment to mentorship demonstrate her leadership and dedication to advancing digital health.
Our next interview in the “Meet the Editors-in-Chief” series is with Prof. Dr. Ola Didrik Saugstad, the editor of the journal Neonatology. Watch this video and learn about:
Research in oxygenation of newborns and preterm babies
Clinical trials on optimal oxygenation of premature babies
The importance of surfactant in the lungs of premature babies
The role of pediatric, neonatal, and perinatal medical societies
The development of the European guidelines for the treatment of preterm babies with respiratory distress syndrome
The next interview in the “Meet the Editors-in-Chief” series is with Prof. Dr. Kari J. Syrjänen, the editor of the journal Acta Cytologica. Watch this video and learn about:
Human papilloma virus (HPV) research spanning almost 50 years
The association of HPV with other cancers and the importance of HPV vaccines
International and European Commission funded HPV clinical trials
The next installation of the “Meet the Editors-in-Chief” series is with Prof. Dr. Giorgio Minotti, the editor of the journal Chemotherapy. Find out more about his experiences and learn about:
How the field of pharmacology intersects with other disciplines i.e., oncology, hematology, radiology, and biochemistry
Anti-cancer drugs and his pioneering role in the field of cardio-oncology
New clinical trials with anti-leukemic drugs
Joining scientific/medical societies to become a “citizen of the world”
The importance of guidelines regarding the therapeutic index of new anti-cancer drugs
Our next interview in the “Meet the Editors-in-Chief” series is with Prof. Dr. Giovambattista Capasso, the editor of the journal Kidney and Blood Pressure Research. Watch the video and learn about:
In this special edition of the “Meet the Editors-in-Chief” series, we interviewed two co-editors of the journal Glomerular Diseases, Prof. Dr. Sharon Adler and Prof. Dr. Cynthia Nast. Watch this video and learn more about:
A new precision medicine algorithm that enables patients with rare glomerular diseases to be diagnosed based on molecular signatures
The role of collaborations with biopharmaceutical companies, medical societies, and government agencies to bring new therapies forward
How nephrology societies contribute to guidelines and education, in the service of patients and treatments
Patient education and engagement in glomerular diseases clinical trials
Our next interview on the “Meet the Editors-in-Chief” series highlights Prof. Dr. David Witherington, the editor of our journal Human Development. Watch this video and learn more about:
The development of emotions and cognition in childhood and subjective experience.
Next on our “Meet the Editors-in-Chief” interview series, we interview Prof. Dr. Stefano Cianfarani, the editor of our journal Hormone Research in Paediatrics. Watch this video and learn more about:
The role of AI in the management of children with type 1 diabetes
The latest clinical trials for type 1 diabetes, severe obesity, short stature
How collaborating with the pharmaceutical industry brings about new treatments for paediatric conditions
Welcome to our “Meet the Editors-in-Chief” interview series, where we interview the editors of our journals about their scientific work and their relationship to the journal. First up is Prof. Dr. Dan Atar, Editor-in-Chief of Cardiology,a Transformative Journal model that supports authors and organizations in making a sustainable transition to Open Access, while enabling authors’ publishing preferences. Watch this video and learn about:
Dr. Dan Atar’s background, scientific, and clinical research
We interviewed the Publication Manager and Karger’s Liaison for Researcher Engagement and Recognition, Teresa Mathews, PhD to provide an overview of how we are expanding our Latest in Sleep Research Collection and how you can contribute to the call for papers. Here you can learn more about contributing to our cutting-edge collection of scientific discoveries on sleep.
Sleep disorders are significant for all neurologists and currently a prominent subject in research circles and conferences. Progress in understanding the influence of sleep on health and disease, diagnostics and treatment is widespread and comes from a broad range of medical fields. You can explore how diverse this subject is in our multi-journal collection “Latest in Sleep Research”.
Our internationally recognized and peer-reviewed collection spans topics from sleep quality to sleep disorders, covering a variety of sleep-related conditions and inquiries into the role sleep plays in our overall health. At Karger, we make navigating this complex subject effective and easy while maintaining the full scope and integrity of researchers’ insights.
What motivated the launch of the call for papers titled ‘Epidemiology of Sleep Disorders in Neurology’? How did the collaboration with Prof. Elisa Baldin and Prof. Ambra Stefani start?
Last year, I attended the EAN (European Academy of Neurology) congress in Vienna and had the opportunity to listen to Prof. Elisa Baldin’s talk on Epidemiology of Sleep Disorders in Neurology.
Dr. Elisa Baldin joined Neuroepidemiology’s Board in September 2020, and has right from the start been a very engaged member. I was inspired by Dr. Baldin’s talk and after discussing with Prof. Feigin, we approached her about highlighting this important topic in the journal via a call for papers for a dedicated article collection entitled Epidemiology of Sleep Disorders in Neurology.
What types of articles and topics is Neuroepidemiology looking to add to the collection?
We are accepting reviews, systematic reviews, brief reports, and research articles with a focus on Epidemiology of Sleep Disorders in Neurology.
Why should one contribute to the Epidemiology of Sleep Disorders in Neurology Article collection in Neuroepidemiology?
Our Epidemiology of Sleep Disorders in Neurology collection is an opportunity to highlight an author’s expertise in this field. Contributing to a collection increases the visibility of an author’s work as the papers are showcased in a special landing page side by side to the works of further experts. Article collections are included in special campaigns and distributed to a larger audience via target mailings and social media communications.
How will submissions be evaluated and reviewed?
All manuscripts submitted to this call are to be peer reviewed. After the checks performed by the editorial office, the manuscripts are checked by the Editor-in-Chief for the manuscript scope. Then, the manuscripts are assigned to one of the guest editors who will handle the peer review by inviting independent reviewers with relevant expertise to evaluate the manuscripts and writing recommendations to the Editor-in-Chief regarding the suitability for publication of the manuscripts. Only manuscripts that are successful in the peer review will be published in the journal.
What can authors do to ensure their submissions are considered?
Authors wanting to submit should carefully read the call for papers’ instructions. We kindly request that the authors use the respective article templates to optimize the chances of success at the editorial office checks and to allow manuscripts to be sent to peer-review as quickly as possible.
Important: Authors should mention the call for papers in their cover letter and choose the call for paper Epidemiology of Sleep Disorders in Neurology during the submission. Otherwise, the probability that the submission is included in the collection’s landing page is very low.
Why choose a Karger journal and what sets us apart?
Connecting people and science since 1890, Karger is a pioneer in peer-reviewed publishing in health sciences and has built a reputable portfolio of more than 100 medical journals and 9,000 books. Today, Karger is a leader in providing health sciences publishing and engagement that spans the entire cycle of knowledge. Karger provides reliable and tailored approaches, bringing health sciences to life. With its broad range of products and services, Karger helps authors to publish research papers, and supports organizations to disseminate their scientific findings to a wide audience, engaging with the research community. Neuroepidemiology is a hybrid journal, meaning one can choose to either publish under the subscription model or choose to publish their paper with an Open Access license via Karger Publisher’s Author’s Choice™ service.
Corresponding authors, can check their eligibility to publish Open Access articles at no or reduced cost if they are associated with or employed by one of these universities.
What’s the deadline and where can one submit?
The call for papers has been extended and authors should submit their work by December 20th, 2023, through this Call for Papers page.
The first papers for this collection have been already published.
MORE ABOUT TERESA MATHEWS, PHD
Teresa is a Publication Manager with the Editorial Development team and manages several journals, mostly from Karger’s Neurology and Neurosciences portfolio. She is also Karger’s Liaison for Researcher Engagement and Recognition, and co-leader of the internal task force dedicated to value outstanding published research, the work of reviewers and the leadership of the Karger editors. Outside of work she enjoys reading and learning how to play the piano.
The moment TV was invented, everybody thought it would mean the death of radio. That didn’t happen, though; instead consumer habits changed and adapted. After a while, one could identify a behavioral trend with the introduction of every new media: first an unsubstantiated fear and then the adaption after the initial surge. What does that mean for printed media such as books, journals, and research papers?
The point of research is to present the newest findings in a field and also, hopefully, to sometimes revolutionize the field. To write a research paper, the author needs to find literature to support new scientific findings. We may remember from our days at the university how intensive the writing of even seminar papers could be, imagine writing a research paper!
During my university time, thankfully, I could already find and use online resources, but many decades ago, one had to go to the library and physically flip through books to find what one was looking for. Some scholars even had to travel to libraries in another country because the one book that they were looking for was only available there. This was a very time-intensive process.
Are Only Printed Books the Real Deal?
However, even nowadays, in a very digital time and age, some still prefer the “old-fashioned” method. But why is that so, you might ask? The smell of books cannot be replaced by an e-book, and it’s harder (but not impossible) to add your notes or highlight important sections in a digital text. My mom, for instance, reads more books than anyone I know. I wanted to gift her with an e-reader many times, but she could not be convinced. “I like the smell and feel of books, it reminds me of a happy, uncomplicated time. Scrolling onscreen takes away the magic,” she says. So, I was curious to find out what readers of scientific content prefer when it comes to reading books and articles, printed or online. The infographic below showcases the results of a poll we published on our social media channels.
We can see that print is far from being extinct, but also that online resources are (just as) important. The main issue with physical books is that they are not as up to date as online articles, a physical book (or article) cannot be shared that easily, and you have to physically pack it in your bag, since it’s not automatically in your cloud or on your server. Books are relevant for general theories that withstood the test of time, digitalization, and other factors, but the findings and developments in a field are more likely to be found in recently published online articles.
Even though at Karger, most publications are articles, books and book series had a very significant role decades ago and some are still relevant nowadays. Most of the books are available on- and offline, and some of them are free access and downloadable as a pdf or an e-book file (check out our Fast Facts for patients or clinicians)
With the rising importance of Open Access and Open Science , we turned our focus more and more to online publications, videos, podcasts and other digital channels. Stay tuned for many exciting things that are coming soon!
What does a Community Insight Specialist at Karger do? Nives Vajda told us in an interview about her typical day at work, how she structures her tasks and what she appreciates working at Karger.
Take us through a day in your work life. What are some of the work habits you’ve developed over the years that help you maintain productivity?
My workday is usually a mix of many different activities, depending on where the projects I am working on are at the moment. Doing desk research or analyzing data and writing reports demand a lot of time for quiet, concentrated, analytical work. On the other hand, research planning and data collection are very dynamic, with lots of interactions with colleagues and research participants and many short-term tasks. I try to do the short tasks early in the morning and leave time later in the day for focused work, and break down larger projects into smaller units or tasks to make daily time planning easier.
What motivated you to apply for a position at Karger?
After starting my career in marketing, I later moved on to working on scientific research projects in the field of psychology. I enjoyed working at the university, but I missed the creativity and the dynamic of marketing. This position at Karger attracted me as an optimal opportunity to remain close to the scientific community while being part of a marketing team.
What has been your experience during the remote working over the last two years?
My job interview and onboarding were almost fully remote, so I was used to it from the beginning, and it was not challenging at all. The flexibility of remote work is also very helpful for my interactions with customers — it is much easier to accommodate the scheduling preferences of interview partners from different time zones when working from home.
It was interesting, however, to finally meet everyone in person when we returned to the office, and I am glad that we can now also have an informal exchange over lunch or in the hallway and that I got to know some of my colleagues better.
What do you enjoy the most about your time at Karger?
Openness for new ideas and initiatives. I greatly appreciate working in a team where I have freedom to try out new ideas and build new processes and have positive and constructive discussions with colleagues.
The other thing would be the opportunity to work with and learn from a wide range of experts from various fields both in Karger and in the Karger community. Listening to them to better understand how they work, their motivation and their needs often gives me insights into interesting new areas, opens questions I never thought about before and inspires new ideas.
What would you like someone who’s interested in applying to Karger to know?
That is a difficult question since there are many various roles in the company, but speaking from my experience I would say: you can look forward to a great start. You will be welcomed by a very well-organized onboarding process and kind colleagues happy to answer your questions. You will also have access to a user-friendly digital platform with extensive information about various topics, which allows you to get a better understanding of the company, products, and services in your own time.
What kind of media are you consuming every day?
Other than quickly checking the news and LinkedIn feed, I cannot say that I use any media daily. I am subscribed to many newsletters and follow many professional groups, to better understand the field that I am researching and keep track of new developments, so I visit their pages or take part in their webinars when something interesting comes up. Lately I have been reading a lot about big data and machine learning, especially its impact on society.
Are you interested in a career at Karger? Explore our current job opportunities at our job portal. Also, find out what Adrian does in the role as the “Head of Digital Landscape”.
Below you will find experience reports by participants of the 5th Filmmaking Marathon, whose short films were also shown at the Global Science Film Festival this November (see our previous article about the GSFF). We want to offer congratulations to all and thank them for sharing their experiences. Enjoy the reading!
My name is Tatiana Alonso Amor and I am a postdoc working at the Swiss Tropical and Public Health Institute in Basel. My everyday working life involves producing quantitative evidence to support decision-makers in Africa in their fight against malaria. But what does this mean exactly? With the help of mathematics and some very cool computers, we are able to simulate how different policy scenarios would affect the transmission of the disease. One of the most beautiful aspects of my work is the constant interaction with people from all sorts of backgrounds pursuing the same objective: reduce malaria and thus improving the life quality of many.
When I read that Karger was inviting PhD students and post-docs to participate in the 5th Filmmaking Marathon, it felt like a no-brainer. What better way to learn new ways of communicating complex topics to a wide audience than making a scientific short film? As soon as I sent my application to participate in the event, I started thinking about ideas for the short film. I knew I wanted to talk about the importance of using quantitative evidence for decision-making and highlight that this is something that, in many instances, policy-makers already do. At the same time, I wanted to point out that this is something we also do all the time in everyday life. That is how the idea for “Decisions” started. I teamed up with two great scientists, Lita Palomares and Jagannath Biswakarma, and with Albert Blanch, the amazing filmmaker. Now that the marathon has ended, I am looking into ways to incorporate what I learned into my current work, making short explanatory videos of the work that we do and showcasing how this type of work can help in the fight against malaria.
Science is beautiful, and it’s better when shared and understood by all.
My name is Nicole Friedli, I studied psychology at the University of Zurich and while searching for my PhD position of choice, I’m currently working as a research assistant. In my free time and in the course of previous jobs, I’ve been passionately involved in several commercial, creative, and scientific film projects. Accordingly, when my former professor forwarded me a call for applications to take part in the Scientific Filmmaking Marathon at UZH, I was very excited and immediately applied. Luckily, I was invited by Karger and soon after, I handed in my very own idea of a short film project.
The idea for the movie “What do you know about Molly?” emerged while I was writing my Master’s thesis on white matter alterations in chronic MDMA (also known as ‘ecstasy’) users. While diving into the topic, I was missing an explanatory video combining the acute subjective effects of the substance with the action MDMA takes on the neuronal level.
After my pitch of the idea on the first day of the Filmmaking Marathon, I was very happy that five inspiring researchers and a very competent filmmaker joined the team. We immediately dove into the topic and after three intensive days of story-writing, organising, filming, drawing, animating, and editing, our short film was ready to present to the other participants of the marathon.
I personally think that films are very powerful in transporting scientific findings to a broader audience due to their creative and often entertaining properties. For this reason, a while ago I started planning my own scientific short film series. As I will need skills in animation to realise my project, during the filmmaking marathon I concentrated on the animations for our short film. As expected, the event served as the perfect opportunity to gain introductory knowledge in this field. And last but not least, seeing all the beautiful projects other researchers and their mentors created as well as finally seeing our finalised project on the Filmpodium screen alongside movies by professional filmmakers was a huge motivational boost for further projects.
I’m Christoph Häfelfinger and I’m a medical student in my second clinical year, currently working on my Master’s thesis in a neuroscience lab. For the future I am planning on becoming a surgeon and a scientist. In learning how to make a film, we as scientists get the potential to present our thoughts and work in an emotionally captivating and graphic way. Personally, I am convinced that new forms of communication, such as short films, have the potential to bridge the contemporary trust gap between science and society. Thus I am thus very thankful to Karger Publishers for making this amazing workshop happen and inviting me to participate in it!
At the Filmmaking Marathon (FMM), I was able to connect with a team of amazing scientists with diverse talents. In our piece “What do you know about Molly” we did our best to illustrate the effects of MDMA (ecstasy) on two levels: its action in the brain and its effects on the human. In achieving our goal, we managed to acquire new skills in animation and acting. By aligning our creativity and experience, we were able to create an exciting piece tailored towards various knowledge levels (I hope you enjoy it!).
The FMM has sparked the idea of creating a YouTube channel for conveying scientific topics to a broader public. I am very excited to use and further develop my newly learned skills with a colleague with whom I was working on the MDMA movie. Further down the road I also see myself using filmmaking in my own scientific and clinical work as a surgeon in order to break down abstract concepts into tangible pieces of information.
I am Celestin Mutuyimana from Rwanda and I am a PhD student at the University of Zurich Department of Psychology in Switzerland. My area of interest is trauma-related disorders, focusing on identifying unrecognised long-term effects of trauma and the corresponding healing strategies. Because of the history of genocide against the Tutsi in my country in 1994, I had a big dream to become an activist for positive social change, resilience, and trauma healing in the community. Since then, I have developed three strategies to achieve my goal: Research, community-based therapy, and making films for a wide audience. I tried the two strategies but I had no idea how to implement my last strategy. I was very busy with research and thought it was not possible to combine research and filmmaking.
Surprisingly, I found an ad from Karger Publishers inviting scientists to participate in the Filmmaking Marathon. The invitation message was very motivating and showed how useful it is for scientists to connect their scientific knowledge with film and bridge the gap between scientists and the general public. As a result, I applied and my application was positively received and supported by Karger Publishers and I received a ticket for the Filmmaking Marathon.
During the marathon, I made a film showing how trauma survivors live for long periods with collective and cumulative unhealed psychological wounds that can only be healed through a specific community-centered and cultural approach. Through this process of filmmaking, we learned a lot of useful skills. First, we learned how to put a scientific idea into a form that an audience can understand. Second, we learned how to create a script for a film and make it short and stable. We had the opportunity to film, take photographs, and edit videos. Finally, with the help of professional filmmakers, we learned different strategies to find the appropriate music, footage, and images for the film. I plan to use these skills in making more videos aimed to help survivors heal their traumatic wounds. So I think film studies is important because it helps bridge the gap between science and society; it helps scientists improve their creativity, use their talents, and network with other people.
My name is Lita Palomares, and I’m from Peru. Currently, I’m doing my PhD in Public Health & Epidemiology at the University of Basel. Also, I have a Master’s in Food and Nutrition Management and Teaching, and a professional degree as a Licentiate in Nutrition. I wanted to take part in the 5th Science Filmmaking Marathon 2021 because I have loved movies since I was a child; I feel that we can learn so much through a good movie, documentary or short film. I found that this Filmmaking Marathon experience was full of learning experiences for me.
My short film, “Decisions”, was made by an international team and invites us to reflect on how we make decisions every day in our lives. This short film emphasizes that we must trust in science. I plan to continue using the skills I acquired for the future and someday make a full-length film. I strongly believe as a scientist that it is important to communicate our findings in a way that is easy to understand for every member of the public, and audiovisual projects help us to do that. Finally, I learned something very important in the 4th Global Science Film Festival, namely that the shortest distance between science and society is cinema.
Watch the short films “Soul Wound”, “What do you know about Molly”, “Decisions” and others.
Victoria is responsible for Social Media at Karger and the expert for #hashtags. She is also actively involved in managing this blog. In her free time, you can find her doing sports, figuring out how to get most views for her Reels, and learning Spanish.
Welcome to our “Meet the Editors-in-Chief” interview series, where we interview the editors of our journals about their scientific work and their relationship to the journal. First up is 
Take us through a day in your work life. What are some of the work habits you’ve developed over the years that help you maintain productivity?